Concepedia

Philip Fanning

PF

Statistics

Publications

7

Citations

217

H-Index

7

Active since

2018

Affiliations

Start Treatment & Recovery Centers(Current)

South Texas Accelerated Research Therapeutics

University of Colorado Denver

Samsung Medical Center

University of Colorado Cancer Center

Philip Fanning is an author at Start Treatment & Recovery Centers specializing in cancer immunotherapy, immunotherapy, and pharmacotherapy.

Publications per year

2018–2025

7

Publications

7

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Nehal J. Lakhani, Laura Q.M. Chow, Justin F. Gainor et al. · Seoul National University Open Repository (Seoul National University) · 2021 · 95 citations

Pharmacy, Oncology, Pharmacotherapy +9

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, Nehal J. Lakhani, Justin F. Gainor et al. · Blood · 2019 · 26 citations

Life Sciences, Immunology, Pharmacotherapy +9

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, Nehal J. Lakhani, Justin F. Gainor et al. · Blood · 2020 · 25 citations

Medicine, Pharmacology, Pharmacotherapy +8

A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.

Nehal J. Lakhani, Patricia LoRusso, Navid Hafez et al. · Journal of Clinical Oncology · 2018 · 20 citations

Pharmacy, Immunology, Pharmacotherapy +17

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.

Laura Q.M. Chow, Justin F. Gainor, Nehal J. Lakhani et al. · Journal of Clinical Oncology · 2020 · 20 citations

Medicine, Oncology, Pharmacology +17

1–5 of 7